This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Myrexis Announces Azixa(TM) Clinical Data Publications

Phase 1 Clinical Data Published by Molecular Cancer Therapeutics Pre-Clinical, Phase 1 and 2 Clinical Data Review Published by Drugs of the Future

SALT LAKE CITY, Feb. 3, 2011 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced the publication of two peer-reviewed journal articles describing the clinical data to date for Azixaâ„¢ (MPC-6827, verubulin). Azixa is the Company's lead compound currently under evaluation in a two-arm, Phase 2b clinical study for first-line treatment of glioblastoma multiforme (GBM), an aggressive form of primary brain cancer.

  • Azixa Phase 1 clinical data was described by lead clinical investigators at The University of Texas M. D. Anderson Cancer Center and The University of Utah, Huntsman Cancer Institute in an article titled "Phase I Clinical Trial of MPC-6827 (Azixa), a Microtubule Destabilizing Agent, in Patients with Advanced Cancer," published in the December 2010 issue of Molecular Cancer Therapeutics.  
  • Updated pre-clinical and clinical data including two completed Phase 2 studies of Azixa in combination with standard chemotherapies for the treatment of brain tumors were highlighted in the December 2010 edition of Drugs of the Future by lead investigator Lawrence Recht, M.D., Department of Neurology, Stanford University School of Medicine.

Myrexis recently announced the initiation of a Phase 2b, comparative-arm, clinical study of Azixa in the front-line treatment of GBM. An open-label, Phase 2a single-agent study of Azixa is currently ongoing for the second- and third-line treatment of recurrent GBM. The Company recently presented promising preliminary data from a subset of patients who had failed both first-line temozolomide and second-line Avastin treatments. Data from the second sub-group of recurrent GBM patients in this study who are naïve to Avastin treatment are expected in the first half of 2011.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs